Alectinib Granted FDA Priority Review for ALK-positive NSCLC

Share this content:
The FDA granted priority review to alectinib for the treatment of patients with ALK-positive, locally advanced or metastatic NSCLC.
The FDA granted priority review to alectinib for the treatment of patients with ALK-positive, locally advanced or metastatic NSCLC.

Editor's note: This article was updated to amend an error in a stated confidence interval.

The US Food and Drug Administration (FDA) has granted priority review to alectinib for the treatment of patients with ALK-positive, locally advanced or metastatic non–small cell lung cancer (NSCLC).1

Alectinib was previously granted accelerated approval for the treatment of ALK-positive metastatic NSCLC resistant to crizotinib.

The FDA granted priority review based on evidence from the phase 3 ALEX (ClinicalTrials.gov Identifier: NCT02075840) and J-ALEX trials, the latter of which was conducted in Japan.

For the ALEX trial, researchers randomly assigned 303 treatment-naive patients with ALK-positive NSCLC to receive alectinib 600 mg twice daily or crizotinib 250 mg twice daily.

Alectinib decreased the risk of disease-progression and death by 53% vs crizotinib (hazard ratio [HR], 0.47; 95% CI, 0.34-0.65; P <.0001).

Patients receiving alectinib did not reach investigator-reported median progression-free survival (PFS) (95% CI, 17.7-not reached) vs 11.1 months (95% CI, 9.1-13.1) in the crizotinib arm. The independent review committee–reported median PFS was 25.7 months (95% CI, 19.9-not reached) for the alectinib group vs 10.4 months (95% CI: 7.7-14.6) for the crizotinib group (HR, 0.50; 95% CI, .036-0.70; P < .0001).

The risk of progression into the central nervous system was reduced by 84% (HR, 0.16; 95% CI, 0.10-0.28; P < .0001) with alectinib compared with crizotinib.

RELATED: Study Predicts Important Role for SABR in Treatment of Early-stage NSCLC

The J-ALEX trial results also showed favorable efficacy.2

Both the ALEX and J-ALEX trials reported a lower frequency of grade 3 to 5 adverse events in the alectinib group vs the crizotinib group.

A decision for approval will be made by November 30, 2017.

References

  1. FDA grants Genentech's alecensa priority review for initial treatment of people with ALK-positive lung cancer [news release]. South San Francisco, CA: BusinessWire; August 3, 2017. http://www.businesswire.com/ news/home/20170802006635/en/FDA-Grants-Genentech%E2%80%99s-Alecensa-Priority-Review-Initial. Accessed August 3, 2017.
  2. Hida T, Nokihara H, Kim YH, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomized phase 3 trial. Lancet.  2017;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters